Analytical recommendations: Anticipated increase of up to 65% in these specific stocks' value
In the ever-evolving world of finance and technology, three companies are currently standing out as potential candidates for significant gains in the medium term: Nuvei Corp., Merus NV, and PepGen Inc. Here's a closer look at each of these companies and their current growth prospects.
Nuvei Corp.
Nuvei Corp., a Canadian fintech company, offers technologies to optimize electronic payments for merchants and partners worldwide. The company serves merchants and partners in North America, Europe, and various other parts of the world. Notably, Nuvei Corp.'s stock is currently being evaluated by analysts for potential price surges.
According to UBS analyst Timothy Chiodo, Nuvei Corp. is a buy, with a price target of $30. This suggests a potential growth of over 26%. The average expected price increase for Nuvei Corp. on Wall Street for the next 12 months is 36%.
Although there are no specific up-to-date 12-month stock price growth forecasts for Nuvei Corp., it's worth noting that the company was acquired in mid-2025 at $34 per share. This acquisition might have impacted its stock status and future public trading and forecasting availability.
Merus NV
Merus NV, a biotechnology company specializing in clinical oncology, is another company worth watching. Analysts predict an upside of 31% for Merus NV, with a current price target of $66, indicating a potential growth of 40%.
However, it's important to note that the search results do not include any data or forecasts specific to Merus NV's stock.
PepGen Inc.
PepGen Inc, a biotech company that develops novel oligonucleotide transport technologies, has already seen significant growth this year. Since the beginning of the year, PepGen Inc's stock has already risen by over 100%. The company is primarily for speculative investors.
Despite this impressive growth, there are no stock price growth forecasts or other financial performance details available for PepGen Inc. in the search results. However, Wainwright analyst Andrew Fein maintains a price target of $26 for PepGen Inc, indicating a current growth potential of over 80%.
Analysts predict a 65% upside for PepGen Inc., making it a stock that could rise by double digits in the near future.
For the latest and precise forecasts for these companies, consulting specialized financial platforms, official company disclosures, or analyst reports covering these companies directly would be necessary.
Investing in Nuvei Corp., a Canadian fintech company, could yield potential gains as analysts have suggested a growth of over 26%, with a price target of $30. On the other hand, Merus NV, a biotechnology company, is forecasted to have an upside of 31% with a price target of $66. Meanwhile, PepGen Inc., specializing in biotech, has already seen a rise of over 100% this year, with up to an 80% growth potential predicted by analyst Andrew Fein.
